In the changed post COVID-19 business landscape, the global market for Somatostatin Analogs estimated at US$6. 7 Billion in the year 2020, is projected to reach a revised size of US$10. 1 Billion by 2027, growing at a CAGR of 6.

New York, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Somatostatin Analogs Industry" - https://www.reportlinker.com/p06032950/?utm_source=GNW
1% over the analysis period 2020-2027. Octreotide, one of the segments analyzed in the report, is projected to record a 5.1% CAGR and reach US$4.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Pasireotide segment is readjusted to a revised 7.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 9.5% CAGR

The Somatostatin Analogs market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 9.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.4 Billion by the year 2027.



Lanreotide Segment to Record 6.1% CAGR

In the global Lanreotide segment, USA, Canada, Japan, China and Europe will drive the 6.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$802.1 Million in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 7.4% CAGR through the analysis period.

Select Competitors (Total 43 Featured) -
Camurus AB
Chiasma Inc.
Crinetics Pharmaceuticals
Dauntless Pharmaceuticals
Ipsen Pharma
Midatech Pharma PLC
Novartis AG
Peptron, Inc
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals Inc


Read the full report: https://www.reportlinker.com/p06032950/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Somatostatin Analogs - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Somatostatin Analogs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Somatostatin Analogs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Somatostatin Analogs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Octreotide by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Octreotide by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Octreotide by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Pasireotide by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Pasireotide by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Pasireotide by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Lanreotide by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Lanreotide by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Lanreotide by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Acromegaly by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Acromegaly by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Acromegaly by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Neuroendocrine Tumors (NETs) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Neuroendocrine Tumors
(NETs) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Neuroendocrine Tumors
(NETs) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027

Table 19: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Somatostatin Analogs Market Analysis of Annual
Sales in US$ Million for Years 2012 through 2027

III. MARKET ANALYSIS

UNITED STATES
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 23: USA Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 24: USA Historic Review for Somatostatin Analogs by Type -
Octreotide, Pasireotide and Lanreotide Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 25: USA 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 26: USA Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 27: USA Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 28: USA 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

CANADA
Table 29: Canada Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 30: Canada Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 31: Canada 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 32: Canada Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 33: Canada Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 34: Canada 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

JAPAN
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 35: Japan Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 36: Japan Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 37: Japan 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 38: Japan Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 39: Japan Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 40: Japan 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

CHINA
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 41: China Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 42: China Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 43: China 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 44: China Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 45: China Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 46: China 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

EUROPE
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Table 47: Europe Recent Past, Current & Future Analysis for
Somatostatin Analogs by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 48: Europe Historic Review for Somatostatin Analogs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 49: Europe 15-Year Perspective for Somatostatin Analogs
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2021 & 2027

Table 50: Europe Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 51: Europe Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 52: Europe 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 53: Europe Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 54: Europe Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 55: Europe 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

FRANCE
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 56: France Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 57: France Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 58: France 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 59: France Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 60: France Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 61: France 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

GERMANY
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2022 (E)
Table 62: Germany Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 63: Germany Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 64: Germany 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 65: Germany Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 66: Germany Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 67: Germany 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

ITALY
Table 68: Italy Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 69: Italy Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 70: Italy 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 71: Italy Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 72: Italy Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 73: Italy 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

UNITED KINGDOM
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2022 (E)
Table 74: UK Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 75: UK Historic Review for Somatostatin Analogs by Type -
Octreotide, Pasireotide and Lanreotide Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 76: UK 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 77: UK Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 78: UK Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 79: UK 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

SPAIN
Table 80: Spain Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 81: Spain Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 82: Spain 15-Year Perspective for Somatostatin Analogs by
Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 83: Spain Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 84: Spain Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 85: Spain 15-Year Perspective for Somatostatin Analogs by
Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

RUSSIA
Table 86: Russia Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 87: Russia Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 88: Russia 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 89: Russia Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 90: Russia Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 91: Russia 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

REST OF EUROPE
Table 92: Rest of Europe Recent Past, Current & Future Analysis
for Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 93: Rest of Europe Historic Review for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 94: Rest of Europe 15-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2012, 2021 &
2027

Table 95: Rest of Europe Recent Past, Current & Future Analysis
for Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 96: Rest of Europe Historic Review for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 97: Rest of Europe 15-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2012, 2021 & 2027

ASIA-PACIFIC
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Table 98: Asia-Pacific Recent Past, Current & Future Analysis
for Somatostatin Analogs by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 99: Asia-Pacific Historic Review for Somatostatin Analogs
by Geographic Region - Australia, India, South Korea and Rest
of Asia-Pacific Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 100: Asia-Pacific 15-Year Perspective for Somatostatin
Analogs by Geographic Region - Percentage Breakdown of Value
Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2021 & 2027

Table 101: Asia-Pacific Recent Past, Current & Future Analysis
for Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 102: Asia-Pacific Historic Review for Somatostatin
Analogs by Type - Octreotide, Pasireotide and Lanreotide
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 103: Asia-Pacific 15-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2012, 2021 &
2027

Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 105: Asia-Pacific Historic Review for Somatostatin
Analogs by Application - Acromegaly, Neuroendocrine Tumors
(NETs) and Other Applications Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 106: Asia-Pacific 15-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2012, 2021 & 2027

AUSTRALIA
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Australia for 2022 (E)
Table 107: Australia Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 108: Australia Historic Review for Somatostatin Analogs
by Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 109: Australia 15-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2012, 2021 &
2027

Table 110: Australia Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 111: Australia Historic Review for Somatostatin Analogs
by Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 112: Australia 15-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2012, 2021 & 2027

INDIA
Somatostatin Analogs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in India for 2022 (E)
Table 113: India Recent Past, Current & Future Analysis for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 114: India Historic Review for Somatostatin Analogs by
Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 115: India 15-Year Perspective for Somatostatin Analogs
by Type - Percentage Breakdown of Value Sales for Octreotide,
Pasireotide and Lanreotide for the Years 2012, 2021 & 2027

Table 116: India Recent Past, Current & Future Analysis for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 117: India Historic Review for Somatostatin Analogs by
Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 118: India 15-Year Perspective for Somatostatin Analogs
by Application - Percentage Breakdown of Value Sales for
Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications
for the Years 2012, 2021 & 2027

SOUTH KOREA
Table 119: South Korea Recent Past, Current & Future Analysis
for Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 120: South Korea Historic Review for Somatostatin Analogs
by Type - Octreotide, Pasireotide and Lanreotide Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 121: South Korea 15-Year Perspective for Somatostatin
Analogs by Type - Percentage Breakdown of Value Sales for
Octreotide, Pasireotide and Lanreotide for the Years 2012, 2021 &
2027

Table 122: South Korea Recent Past, Current & Future Analysis
for Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 123: South Korea Historic Review for Somatostatin Analogs
by Application - Acromegaly, Neuroendocrine Tumors (NETs) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 124: South Korea 15-Year Perspective for Somatostatin
Analogs by Application - Percentage Breakdown of Value Sales
for Acromegaly, Neuroendocrine Tumors (NETs) and Other
Applications for the Years 2012, 2021 & 2027

REST OF ASIA-PACIFIC
Table 125: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Somatostatin Analogs by Type - Octreotide,
Pasireotide and Lanreotide - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 126: Rest of Asia-Pacific Historic Review for
Somatostatin Analogs by Type - Octreotide, Pasireotide and
Lanreotide Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 127: Rest of Asia-Pacific 15-Year Perspective for
Somatostatin Analogs by Type - Percentage Breakdown of Value
Sales for Octreotide, Pasireotide and Lanreotide for the Years
2012, 2021 & 2027

Table 128: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 129: Rest of Asia-Pacific Historic Review for
Somatostatin Analogs by Application - Acromegaly,
Neuroendocrine Tumors (NETs) and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 130: Rest of Asia-Pacific 15-Year Perspective for

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032950/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001